Company news
Liaoning Chengda Biotechnology Co. Ltd. Class A (SSE:688739) news
Liaoning Chengda Biotechnology Co. Ltd. Class A news releases on 6ix. Latest, Sep 25, 2026: "LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Change…
Press releases & updates
"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Change of Registered Capital and Amendments to the Articles of Association
September 24, 2026
"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Expiration of Shareholding Reduction Plan of Senior Executive and Results of Shareholding Reduction
September 21, 2026
"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing
September 14, 2026
"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026
August 24, 2026
"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on the Results of the Special Governance Review by the Audit Committee of the Board of Directors
August 20, 2026
"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on the Initiation of Phase I Clinical Trial for Influenza Vaccine (Split Virion, High-Dose)
July 17, 2026
"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
July 10, 2026
"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on the Influenza Virus Split Vaccine Obtaining Drug Registration Certificate and Passing GMP Compliance Inspection
July 2, 2026
Announcement on Obtaining Drug Registration Certificate for Quadrivalent Influenza Vaccine (Split Virion) and Passing GMP Compliance Inspection for Drugs
June 16, 2026
Announcement on Implementation Result of Shares Repurchase and Share Changes
June 11, 2026
Announcement on Progress in Joint Investment with the Controlling Shareholder and Its Wholly-owned Subsidiary and Related Party Transactions
June 5, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
June 2, 2026
Announcement on Shareholding Reduction Plan for Senior Management Members
May 28, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 27, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 12, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
April 28, 2026
Announcement on 2025 Annual Profit Distribution Plan
April 20, 2026
Announcement on Obtaining the Approval for Supplementary Application for Drugs for the Core Product Freeze-dried Rabies Vaccine (Vero Cells)
April 17, 2026
Announcement on the Resignation of Independent Directors upon Expiration of Their Term
March 17, 2026
Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for Drugs
March 9, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Obtaining the Drug Registration Certificate for Freeze-dried Rabies Vaccine (Human Diploid Cell)
February 24, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials for Influenza Virus Split Vaccine (High Dose)
February 12, 2026
Announcement on Outward Investing in Establishing a Wholly-owned Subsidiary
January 26, 2026
Announcement on Subsidiary Opening a Special Account for Raised Funds and Signing a Tripartite Supervision Agreement on Special Account Deposit of Raised Funds
January 5, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
December 31, 2025
Announcement on Adjusting the Internal Investment Structure of Partial Investment Projects Financed by Raised Funds
December 18, 2025
Announcement on the Postponement of Certain Fundraising Projects, Adjustment of Internal Investment Structure, and Capital Injection to Wholly-owned Subsidiaries for the Implementation of New Fundraising Subprojects
December 5, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 20, 2025
Announcement on Using Partial Idle Raised Funds for Cash Management
October 29, 2025
Announcement on Voluntary Disclosure of Signing Strategic Cooperation Agreement
October 21, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 1, 2025
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025
August 28, 2025
Announcement on the 1st Repurchase of Repurchased Shares through Call Auction
August 25, 2025
Announcement on Change of Directors of the Company
August 12, 2025
Announcement on Changing the Secretary of the Board of Directors
July 29, 2025
Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders Without Sales Limit Concerning Shares Repurchase
June 24, 2025
Announcement on Resolution of the 19th Meeting of the 5th Board of Directors
June 19, 2025
Indicative Announcement on the Chairman's Proposal to Repurchase the Company's Shares
June 17, 2025
Announcement on Implementation of Dividend Distribution of 2024
June 3, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 14, 2025
Report for Q1 2025
April 29, 2025
Announcement on Convening Performance Briefing for 2024 and Q1 2025
April 24, 2025
Notice on Convening the 2024 Annual General Meeting
April 23, 2025
Announcement on Listing and Circulation of Some Restricted Stocks in Initial Public Offering
April 18, 2025
Announcement on Completion of Share Delivery for Tender Offer for Company Shares by Shaoguan Gaoteng Enterprise Management Co., Ltd.
April 11, 2025
Announcement on Result of Tender Offer and Stock Resumption for Shaoguan Gaoteng Enterprise Management Co., Ltd.
April 7, 2025
Announcement on Expiration of Tender Offer and Stock Suspension of Shaoguan Gaoteng Enterprise Management Co., Ltd.
April 3, 2025
Third Indicative Announcement on Tender Offer for Company Shares by Shaoguan Gaoteng Enterprise Management Co., Ltd.
March 27, 2025
Second Indicative Announcement on Tender Offer for Company Shares by Shaoguan Gaoteng Enterprise Management Co., Ltd.
March 20, 2025